650 related articles for article (PubMed ID: 32425222)
1. Repurposing chlorpromazine to treat COVID-19: The reCoVery study.
Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
Encephale; 2020 Jun; 46(3):169-172. PubMed ID: 32425222
[TBL] [Abstract][Full Text] [Related]
2. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine.
Plaze M; Attali D; Prot M; Petit AC; Blatzer M; Vinckier F; Levillayer L; Chiaravalli J; Perin-Dureau F; Cachia A; Friedlander G; Chrétien F; Simon-Loriere E; Gaillard R
Int J Antimicrob Agents; 2021 Mar; 57(3):106274. PubMed ID: 33387629
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
5. Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
Duvignaud A; Lhomme E; Pistone T; Onaisi R; Sitta R; Journot V; Nguyen D; Peiffer-Smadja N; Crémer A; Bouchet S; Darnaud T; Poitrenaud D; Piroth L; Binquet C; Michel JF; Lefèvre B; Lebeaux D; Lebel J; Dupouy J; Roussillon C; Gimbert A; Wittkop L; Thiébaut R; Orne-Gliemann J; Joseph JP; Richert L; Anglaret X; Malvy D;
Trials; 2020 Oct; 21(1):846. PubMed ID: 33050924
[TBL] [Abstract][Full Text] [Related]
6. Potential COVID-19 therapeutics from a rare disease: weaponizing lipid dysregulation to combat viral infectivity.
Sturley SL; Rajakumar T; Hammond N; Higaki K; Márka Z; Márka S; Munkacsi AB
J Lipid Res; 2020 Jul; 61(7):972-982. PubMed ID: 32457038
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.
Hosoki K; Chakraborty A; Sur S
J Allergy Clin Immunol; 2020 Aug; 146(2):285-299. PubMed ID: 32624257
[TBL] [Abstract][Full Text] [Related]
8. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
9. Psychiatry and COVID-19: The Role of Chlorpromazine.
Stip E
Can J Psychiatry; 2020 Oct; 65(10):739-740. PubMed ID: 32536208
[No Abstract] [Full Text] [Related]
10. Advances and challenges in the prevention and treatment of COVID-19.
Han YJ; Ren ZG; Li XX; Yan JL; Ma CY; Wu DD; Ji XY
Int J Med Sci; 2020; 17(12):1803-1810. PubMed ID: 32714083
[TBL] [Abstract][Full Text] [Related]
11. A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial.
García IG; Rodriguez-Rubio M; Mariblanca AR; de Soto LM; García LD; Villatoro JM; Parada JQ; Meseguer ES; Rosales MJ; González J; Arribas JR; Carcas AJ; de la Oliva P; Borobia AM
Trials; 2020 Jun; 21(1):466. PubMed ID: 32493475
[TBL] [Abstract][Full Text] [Related]
12. Combating devastating COVID-19 by drug repurposing.
Pawar AY
Int J Antimicrob Agents; 2020 Aug; 56(2):105984. PubMed ID: 32305589
[TBL] [Abstract][Full Text] [Related]
13. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
[TBL] [Abstract][Full Text] [Related]
14. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
15. [Informations on psychotropics and their adaptations for patients suffering from mental disorders in France during the SARS-CoV-2 epidemic].
Javelot H; Llorca PM; Drapier D; Fakra E; Hingray C; Meyer G; Dizet S; Egron A; Straczek C; Roser M; Masson M; Gaillard R; Fossati P; Haffen E
Encephale; 2020 Jun; 46(3S):S14-S34. PubMed ID: 32376004
[TBL] [Abstract][Full Text] [Related]
16. Interferon β-1a (IFNβ-1a) in COVID-19 patients (INTERCOP): study protocol for a randomized controlled trial.
Bosi E; Bosi C; Rovere Querini P; Mancini N; Calori G; Ruggeri A; Canzonieri C; Callegaro L; Clementi M; De Cobelli F; Filippi M; Bregni M
Trials; 2020 Nov; 21(1):939. PubMed ID: 33225960
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
18. [Challenges for psychotropics in the context of the SARS-Cov-2 pandemic].
Javelot H; Llorca PM; Meyer G; Fossati P; Haffen E
Encephale; 2020 Jun; 46(3S):S116-S118. PubMed ID: 32360037
[TBL] [Abstract][Full Text] [Related]
19. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
Bimonte S; Crispo A; Amore A; Celentano E; Cuomo A; Cascella M
In Vivo; 2020 Jun; 34(3 Suppl):1597-1602. PubMed ID: 32503817
[TBL] [Abstract][Full Text] [Related]
20. Drug repurposing and cytokine management in response to COVID-19: A review.
Heimfarth L; Serafini MR; Martins-Filho PR; Quintans JSS; Quintans-Júnior LJ
Int Immunopharmacol; 2020 Nov; 88():106947. PubMed ID: 32919216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
